Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AC220: Preliminary Phase I data

Preliminary data from an ongoing, open-label, dose-escalation Phase I trial in

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE